Asia-Pacific self-injection market is expected to reach USD 9,501.12 million by 2024 from USD 3,731.57 million in 2016, at a CAGR of 12.4% in the forecast period 2017 to 2024.
Asia Pacific is the fastest-growing market for self-injection The self-injection market in the Asia-Pacific region is leading in China, India, Japan, and South Korea.
Based on geography, the Asia-Pacific self-injection market is segmented into 11 geographical regions, such as,

Japan,
China,
South Korea,
India,
Australia,
Singapore,
Thailand,
Malaysia,
Indonesia,
Philippines and
Rest of Asia-Pacific.

Asia-Pacific self-injection market competition by top players including -

Sanofi is going to dominate the Asia-Pacific self-injection market following with Becton, Dickonson and Company, Novo Nordisk, Pfizer, along with others such as
Gerresheimer AG,
Mylan N.V. ,
UNILIFE CORPORATION,
West Pharmaceutical Services, Inc.,
Ypsomed, Impax Laboratories, Inc.

The Asia-Pacific self-injection market is segmented on the basis of product type, application, usage pattern, mode of administration, end user, distribution channel and geography.
On the basis of Asia-Pacific self-injection market is segmented into 4 types, namely needle free injectors (NFI), auto injectors, pen injectors, and wearable injectors.

On the basis of applications, the global self-injection market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.

On the basis of usage pattern the global self-injection market is segmented into curative care, immunization.

Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.

On the basis of end user the global self-injection market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.

Based on distribution channel, global self injection market is segmented into hospital pharmacy, Pharmacy stores, direct tender and online pharmacy.